Conformis, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark A. Augusti
- Full Time Employees
- 295
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 600 Technology Park Drive Billerica MA United States of America 01821
- IPO Date
- Jul 1, 2015
- CIK
- 0001305773
- Website
- conformis.com
- Similar Companies
- Business
- Conformis, Inc. is a medical technology company specializing in customized, patient-specific knee and orthopedic joint replacement products and services. The company offers a range of core products including personalized knee implants, surgical planning software, and associated surgical instrumentation, all designed to optimize fit and function for individual patients. Conformis operates primarily in the orthopedic medical device industry, serving hospitals, orthopedic surgeons, and healthcare providers across the United States and select international markets. Founded in 2004 and headquartered in Billerica, Massachusetts, Conformis leverages advanced imaging technology and proprietary manufacturing processes to produce one-of-a-kind implants tailored through 3D modeling and direct digital manufacturing. In recent years, Conformis has pursued strategic business expansions including new product development and potential collaborations aimed at enhancing its technology platform and broadening its market presence. Notably, the company has introduced next-generation solutions in patient-specific joint replacement and has been engaging in partnerships to improve clinical outcomes and expand its footprint in orthopedics. These efforts align with Conformis's focus on innovation in personalized medicine and precision orthopedic surgery. The company continues to explore growth opportunities through new product launches and targeted operational enhancements to strengthen its competitive position in a rapidly evolving healthcare environment. Conformis's business segments primarily include personalized joint replacement implants encompassing total knee, partial knee, and revision knee products, with software and services designed to support surgical planning and execution. Its offerings emphasize improved patient outcomes through customization, addressing diverse anatomical variations and clinical needs. The company's target markets span orthopedic surgeons and healthcare institutions seeking advanced solutions for joint replacement surgery. Overall, Conformis stands out in the orthopedic device industry by combining proprietary technology with personalized care, backed by continuous innovation and strategic business initiatives focused on expanding product lines and improving surgical outcomes. It operates as a public company listed under the ticker symbol CFMS. This description captures Conformis's key products, recent strategic movements, industry positioning, and corporate background comprehensively and professionally.
Scaling a Personalized Portfolio: restor3d Completes Key Initiative Following Conformis Acquisition
restor3d Completes Acquisition of Conformis
Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote “FOR” the Pending Merger with restor3d
ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates
Conformis Reports Second Quarter 2023 Financial Results
CONFORMIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Conformis, Inc. - CFMS
Shareholder Alert: Ademi LLP investigates whether Conformis, Inc. has obtained a Fair Price in its transaction with restor3d
Shareholder Alert: Ademi LLP investigates whether Conformis, Inc. has obtained a Fair Price in its transaction with restor3d
CFMS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Conformis, Inc. Is Fair to Shareholders
Conformis stock nearly doubles in active trading after cash buyout deal with Restor3d
Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash
ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates
Conformis, Inc. (CFMS) Q1 2023 Earnings Call Transcript
Conformis Reports First Quarter 2023 Financial Results
Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023
Conformis Launches Patient Awareness Campaign to Highlight the Benefits of Personalized Knee Replacement Procedures
ConforMIS (CFMS) Moves to Buy: Rationale Behind the Upgrade
Conformis, Inc. (CFMS) Q4 2022 Earnings Call Transcript
Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results
Conformis, Inc. to Participate in Upcoming Investor Conferences